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Introduction
India is the only country in the globe with officially 
recognized multiple systems of medicine, namely Al-
lopathy; Ayurveda; Yoga and Naturopathy; Unani; Sid-
dha; and Homoeopathy [1]. The traditional medicine 
came into the limelight because of the politicization of 
the traditional medicine agenda. India adopted a parallel 
model within the national health care system through the 
Indian Medicine Central Council Act in 1970. The mod-
ern and traditional medicines are separate within this 
[2]. The National Health Policy of 1983 also focuses on 
the Indian Systems of Medicines and Homeopathy. The 
Department of Indian Systems of Medicines and Homoe-
opathy (ISM and H) was established under the Ministry 
of Health and Family Welfare in 1995. This was renamed 
as the Department of Ayurveda; Yoga and Naturopathy; 
Unani; Siddha; and Homoeopathy (AYUSH) in 2003.
The origin of Ayurveda goes back to 5.000 B.C. in 
India. It has been written in Sanskrit language. Unani 
originated in Greece around 980 A.D. and was intro-
duced in India by the Arabs. The literature available is 
in Arabic and Persian language. Siddha originated in the 
southern part of India and the literature available is in 
Tamil language (AYUSH, 2007). After a brief descrip-
tion of the scope of the traditional medicines (Ayurveda, 
Unani, Siddha and some tribal drugs) in India, the issues 
related to their research, standardization and Trade Re-
lated Aspects of Intellectual Property Systems (TRIPS) 
is documented in this article.
Scope of traditional medicines in India
The Indian Pharmacopoeia 2007 (IP) includes 26 
medicinal plants [3]. The essential drug list for dispensa-
ries and hospitals include 340 Ayurvedic drugs and 206 
Unani drugs [4]. The Government of India has added ten 
Ayurvedic and Unani medicines into its family welfare 
programme. They are used for anaemia; oedema during 
pregnancy; postpartum problems such as pain, uterine 
and abdominal complications; difficulties with lactation; 
nutritional deficiencies; and childhood diarrhoea [5].
The traditional medicines are used in chronic and 
debilitating disorders such as heart disease, cancer, 
diabetes and mental disorders. These drugs improve the 
quality of life and help to avoid iatrogenic problems [6]. 
In case of less serious ailments, one third of people in 
India prefer the Indian System of Medicines and Home-
opathy. Moreover, one fifth of them prefer the Ayurvedic 
medicines. However, in case of serious diseases, only 
18% prefer these medicines. About 14% of sick persons 
availed these medicines because of less adverse-effects, 
affordability, effectiveness and accessibility. The reasons 
for not availing these medicines were: less than expected 
effectiveness, unavailability of practitioners, no faith and 
unavailability of medicines. In rural and urban India, 
40% and 30% of households visit the traditional healers, 
respectively. People prefer traditional treatment for ail-
ments such as fractures, animal bites, jaundice, sciatica 
and measles. The preference of people to avail tradition-
al medicines increases with the increase in income and 
literacy level [7]. The prescribing habits of the practi-
tioners vary significantly according to the geographical 
location, practitioner’s background and pharmaceutical 
advertisements [1]. Therefore a drug-utilization survey 
of the traditional medicine teaching hospitals and prac-
titioners should be performed in order to evaluate the 
usage frequency of these drugs.
Contemporary issues of traditional drug use in India
In India, traditional medicines are followed under 
two streams, namely Local Health Tradition, such as 
tribal medicines and Organized System of Medicines, 
such as Ayurveda. The first one is based on the oral tra-
ditions in which many plants were selected on the basis 
This article is the third part in a series of texts entitled: 
“The current problems in drug management in countries of the Indian subcontinent”
tom VI, nr 1–2/2008
leki za granicą
Zeszyty Naukowe Ochrony Zdrowia. Zdrowie Publiczne i Zarządzanie60
leki za granicą
on trial and error in order to treat ailments confronted. 
The latter one is based on the codified written systems 
of medicine with their own theoretical and philosophical 
explanations. The research in the latter stream is better 
than the former one. The respect, preservation, mainte-
nance and validation of drugs associated within the Lo-
cal Health Tradition are seriously lacking. The research 
councils have documented over 10.000 of such folk med-
icines but the level of documentation in this area is still 
incomplete [2]. Therefore, there is an immediate need to 
promote, safeguard and involve such Local Health Tradi-
tion medicines. The tribal communities involved in the 
Local Health Tradition should receive enough funds and 
expertise to codify and preserve their drugs.
The Ayurvedic, Unani and Siddha drugs manufactur-
ing and related matters are covered under the Drugs and 
Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 
1945. In July 2000, new regulations were laid down in 
relation to the standardization of traditional drugs. The 
requirements for infrastructure; manpower; quality con-
trol and authenticity of raw materials; and absence of 
contamination have been mentioned in the regulations. 
There are 9.000 licensed traditional medicine manufac-
turers. Those who satisfy the requirements can seek cer-
tification for good manufacturing practice (GMP). Those 
who cannot satisfy the requirements have two years to 
comply with and to seek the certification. Ten new tra-
ditional drug testing laboratories have been established 
by the Government of India. Moreover, the government 
is upgrading the existing laboratories so that high qual-
ity evidence can be provided to licensing authorities 
on the safety and quality of traditional medicines. This 
has substituted an informal system of testing that was 
considered unreliable and, thus would provide the basis 
for their international licensure as medicines rather than 
simply as food supplements [8]. Pharmexcil was estab-
lished under the Ministry of Commerce and Industry for 
export promotion of pharmaceutical products including 
traditional medicines. Most of the traditional medicine 
exporters are in the medium and small scale sectors that 
needs assistance and guidance. The committee under the 
Pharmexcil provides guidance on heavy metal contami-
nation and acceptable level for the same in the traditional 
drugs. Now, every drug should first fulfill the pharma-
copoeial specifications before the drug is marketed due 
to the growing demand and trade of traditional drugs 
throughout the world [9]. However, quality control, ra-
tional usage, safety and efficacy of traditional medicines 
have not been completely assured till date. The enforce-
ment mechanism has been documented in the Act, and is 
also in place in most of the States of India; however the 
implementation of the enforcement laws remains ques-
tionable. The good manufacturing practices are not fol-
lowed by most of the drug manufacturers. The prepara-
tion of formularies and pharmacopoeial standards are on 
the move but it is not yet completed. There is no assur-
ance whatsoever that formularies and pharmacopoeial 
standards are being followed by the drug manufacturers 
[6]. The adulteration and substitution of traditional drugs 
is a major problem in India. Sometimes people sell raw 
herbs in an open market without any regulation. More-
over, raw herbs are dried in an unhygienic way prior to 
its processing in many pharmaceutical companies. Peo-
ple purchase unregulated medicines from the unlicensed 
vendors leading to irrational use of traditional drugs 
[10]. Therefore, the standardization of traditional drugs 
and enforcement of related laws should be emphasized 
more, both for domestic consumption and for export.
The pharmaceutical companies are not following 
the exact procedures of drug manufacturing as men-
tioned in Ayurveda and therefore the expected results 
are not achieved. Ayurveda addresses the issues of raw 
herb collection for the purpose of drug manufacturing. 
For instance, Phyllanthus emblica fruits should be col-
lected during the months of March and April from the 
Himalayan and sub-Himalayan region as per Ayurveda 
in order to obtain the maximum amount of required con-
stituents [10]. Thus, the pharmaceutical industries should 
follow the accurate procedure of drug manufacturing as 
per Ayurveda.
The clinical research on traditional medicine differs 
from conventional medicine. The economic evaluation 
of traditional medicines compared to conventional medi-
cines is still lacking. The World Health Organization has 
provided guidelines for clinical research in the field of 
traditional medicine. Accordingly, it is ethical to pro-
ceed directly from basic animal toxicity studies to Phase 
III clinical trials in case of a traditional medicine drug 
with an established history of use [11]. However, ethical 
problems come while evaluating traditional drugs. For 
instance, while evaluating an anti-malarial traditional 
drug, the ethics may require the standard conventional 
drug to be given to all subjects which leads to evaluation 
of traditional drug in conjunction with conventional drug 
[2]. Therefore, some alternative models should be devel-
oped in order to evaluate traditional medicines within 
the clinical research. Moreover, the economic evaluation 
of traditional medicines, comparing them with conven-
tional medicines should be started. This would help the 
health experts in making informed choices about the 
selection of medicines to be incorporated into the inte-
grated healthcare programmes.
The Indian Council of Medical Research is conduct-
ing randomized controlled trials on traditional drugs 
which are monitored by the Scientific Advisory Groups. 
These groups consist of experts on the traditional and 
allopathic medicines; pharmacognosy; toxicology; phar-
macology; clinical pharmacology; and standardization 
and quality control. Moreover, these studies are con-
ducted in 20 allopathic clinical trial centers so that tradi-
tional medicines can be integrated into the usage system 
of allopathic hospitals. For example, Picrorhazia kurroa 
and Pterocarpus marsupium are found to be effective 
herbs in hepatitis and diabetes, respectively [12]. Howev-
er, the research has never been reoriented and prioritized 
and thus, has not kept pace with the time [6]. Moreover, 
some pure traditional practitioners oppose this type of 
„modernization” especially when carried out by modern 
scientists in order to bring authenticity to Ayurveda by 
the amalgamation of modern research for further deve-
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lopment. They agree to comply with modern concepts, 
such as conducting randomized controlled trails but 
advocate that not all traditional medicines need to un-
dergo these rigorous trials as these medicines have been 
already in use for ages. Furthermore, the randomized 
controlled trial does not consider the philosophical con-
cepts behind the traditional medicines, such as the body 
constitutions (prakriti in Ayurveda or Mijaj in Unani) of 
the individual which determines the specific medicine to 
be used [10]. Therefore, the research areas should be reo-
riented and prioritized according to the strengths of the 
systems and contemporary relevance. Secondly, clinical 
trails should incorporate the philosophical concepts be-
hind these drugs.
Most of the traditional medicines contain a number of 
ingredients. The research becomes more difficult to per-
form than that of single synthetic compounds, due to the 
presence of a large number of active constituents. Proper 
quality control evaluation systems are employed with the 
help of technological advances in the field of analytical 
chemistry. In order to properly identify the medicinal 
plants at the genetic, species, cultivar or variety level, 
there should be proper markers for quality control of the 
plants themselves. The biological and genomic markers 
as tools for quality assurance can be used in addition 
to chemo-profiling. The move towards molecular and 
system level can be achieved with the help of institutes 
such as the Central Drug Research Institute (CDRI) and 
the National Botanical Research Institute (NBRI). The 
NBRI is presently engaged in examining the medicinal 
plants through either reverse pharmacology or ethno-
pharmacological approach. The Pharmacognosy and 
Ethnopharmacology division of the NBRI has been rec-
ognized as a drug testing center for traditional medicines 
and more than 160 single herbal drugs and a number 
of herbal formulations have been standardized by this 
laboratory [10]. Reverse pharmacology or observational 
therapeutics, emerging at the edge of modern and tradi-
tional medicine has been actively encouraged with utili-
zation projects and centres for excellence, and research 
at all tiers of healthcare. The world may be convinced 
about the evidence-based traditional medicine by this 
approach. Many leads for drugs have been obtained by 
astute clinical observations in the field. The list of drugs 
obtained by the reverse pharmacology path is shown in 
the Figure 1, which could be an economical and effec-
Drugs obtained by the reverse pharmacology path
Indian Other
Medicinal plant Disease Medicinal plant Disease
Rauwolfia serpentina Hypertension Catharanthus roseus Cancer
Commiphora wightii Hyperlipidaemia Cinchona officinalis Malaria
Mucuna pruriens Parkinson disease Digitalis purpuea Heart failure
Picrorrhiza kurroa Hepatitis Salix alba Fever
Curcuma longa Oral cancer Ephedra sinensis Asthma
Figure 1. The reverse pharmacology path of obtaining traditional medicines (Source: Vaidya, 2005 [1]).
Ayurvedic usage
Whole formulations
AYURVEDIC THERAPEUTICS
Medicinal plants
Screening of extracts
Isolation of active principle
Modern drug
Standarize
Exploratory studies
Reverse pharmacology
Experiential documentation
(observations)
Experimental research
Clinical phase II
Natural drugs
R&D paths for natural products
Field use
Standardize
Ethnomedicine
Standard extract
Clinical trials
Herbal remedy
Zeszyty Naukowe Ochrony Zdrowia. Zdrowie Publiczne i Zarządzanie62
leki za granicą
tive drug development path among diverse resource and 
development paths for traditional medicines [1].
The formulation of traditional medicines and medici-
nal plants has been mentioned in the ancient texts and 
treatises. This has attracted many foreign interests and 
unfortunately, a large number of such medicinal uses 
have been patented by the foreign entities, claiming them 
as „innovations” in spite of the fact that they are already 
available in the public domain and so cannot be patented 
under the Intellectual Property Rights (IPR). Unfortu-
nately, the ancient texts and treatises are available in not 
easily accessible form and their language is different 
from the one which is generally used by the foreign pat-
ent examiners. For instance, Ayurveda has been written 
in Sanskrit which is tough to understand by the foreign 
patent examiners. The procedures for reclamation and 
competing patents are very costly and time consuming 
which ultimately hampers the India’s national interest 
[6]. The Trade Related Aspects of Intellectual Property 
Systems (TRIPS) of the World Trade Organization made 
no reference in order to safeguard traditional knowledge. 
Moreover, it had not acknowledged or distinguished the 
indigenous, community based knowledge, and that of 
the industry. The Convention on Biological Diversity 
contested recently with the TRIPS. The World Trade 
Organization in 2002 started harmonizing TRIPS and 
the Convention on Biological Diversity in order to pro-
tect indigenous intellectual and cultural property rights. 
Now the researchers who evaluate traditional medicines 
should be aware of the country of origin of the tradi-
tional drug under the IPR. Prior informed consent and 
just benefit sharing with the country of origin should be 
established in case patent is sought by a non indigenous 
group [2]. Now, the participating countries under the 
TRIPS have the freedom to select the intellectual prop-
erty protection of plant varieties, either under a patent 
regime or a sui generis system or a combination of the 
two. In the sui generis system, an incentive is provided 
to the grass root innovator of the plant based knowledge 
in order to disclose knowledge. In India, a digital library 
for each system of medicine is under development in or-
der to protect India’s traditional medicinal knowledge. It 
will eventually be performed for the uncodified knowl-
edge leading to innovation and good health outcomes 
[6]. On the other hand, the research and policy on tra-
ditional medicines give more focus on the clinical and 
experimental medicine (safety, efficacy and mechanism 
of action) and also on the regulatory and supply-oriented 
issues. They lack the wider public health dimensions, 
such as social, cultural, political and economic, in order 
to enhance the contribution of the traditional medicine 
to the healthcare systems. The ethnicity, culture, famili-
arity and religion play a vital role in the usage of tra-
ditional medicine. The research on safety, efficacy and 
mechanism of action has received more importance from 
the funders than the public health research; because of 
the response the funders received from the biomedical 
community and not from the public health research com-
munity [2]. Therefore, in order to enhance the contribu-
tion of traditional medicine to healthcare systems, public 
health dimensions should be added to the research and 
policy. Moreover, political and scientific intents should 
focus on this issue.
The inter-sectoral cooperation with other Ministries 
and Departments, such as of Culture and Tourism, pro-
mote and propagate the traditional medicines by provid-
ing these medicines or reimbursing their costs [6]. Peo-
ple are paying huge amount of out-of-pocket expenses 
for traditional medicines which are mostly not covered 
under the available health insurances [2].
Use of alternative medicines in Europe
Apart from India, European countries also have 
many popular medicines. These medicines originated 
even many centuries before the era of contemporary 
modern pharmacology. They are often referred to as al-
ternative medicines, which imply that these therapies are 
currently being used as a substitute to the conventional 
therapies. Other terms which are used for this kind of 
medicines are as follows: complementary, unconven-
tional, unorthodox, related to irregular or integrative 
medicine. Some of them are more popular than others, 
depending on the country. The four groups of alternative 
medicines are particularly popular in different countries 
of Europe: homeopathic, herbal (phytotherapy), essential 
oils and flower remedies [13].
Homeopathic drugs which are currently used both in 
India and Europe, originated from the theories propa-
gated by the German scientist Samuel Hahnemann in the 
XIX-th century. The homeopathic medicines are based 
on the principle of „like cures like”. Interestingly, these 
drugs have retained more popularity in India compared 
to most of the European countries. The phytotherapy is 
based on the remedies derived from plants and plant ex-
tracts, and it relies on principles which are shared with 
well-grounded modern science of pharmacology. The va-
riety of currently used herbal products in Europe comes 
not only from this continent (e.g. traditionally used 
folk remedies) but also from far distant locations such 
as China or India. This includes herbs like aloe vera, 
echinacea, garlic, ginkgo, ginseng, kava, feverfew, saw 
palmetto, St John’s wort and valerian. The position of 
essential oils in the alternative medicine is much weaker 
in Europe, and the quite popular form of application of 
essential oils is referred to as aromatherapy. The health 
effects of essential oils are supposed to be both psycho-
logical and physiological. Moreover, these oils also work 
at the cellular level. In the present Europe, the founda-
tion of flower remedies as a form of alternative medicine 
was laid down in the beginning of the XX-th century. 
The mechanism of action of these flower remedies is 
supposed to be through their „energy” and is not related 
to the scientifically grounded pharmacology. Therefore, 
some similarities of this therapy with the homeopathy 
can be found. 
The formal status of availability of alternative medi-
cines to patients is differentiated, ranging from pharma-
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cies to the direct sale. They usually belong to the OTC 
(over the counter, i.e. available without prescription) 
category of drugs. Herbal medicines are more popular 
in Germany (30% of the OTC market) and France (28% 
of the OTC market) [14]. They are also quite popular in 
Poland and the Polish market of herbal products is on 
the second rank within the European countries (after 
Germany). The production of herbal products in Poland 
accounted for 4% of their global production. In 2003, the 
value of global market of herbal products was reported 
to be € 20,000,000,000, out of which € 7,500,000,000 ac-
counted for Europe itself. At the same time, the value 
of Asian market was assessed to be € 5,700,000,000 
and the value of North American market was about 
€ 3,800,000,000 [15].
In some European countries, many herbal or even 
homeopathic products were used to be financed by the 
health insurance, especially until the late 90-s of the 
XX-th century. The reason for withdrawing many of 
these products from the reimbursement systems (such 
as in Germany) was the struggle to reduce the growing 
pharmaceutical public expenditures. There are some in-
teresting historic justifications for inclusion of certain 
traditional therapies into the reimbursement systems. 
For example, when the NHS was created in the UK in 
1948, all alternative medicines were excluded from the 
coverage of public funds, except homeopathic products 
due to the strong royal patronage [13].
The market of the alternative medicines within the 
European Union is growing, and the majority of expens-
es for these medicines are paid out-of-pocket by the pa-
tients. The WHO has issued the same recommendations 
for other countries (including the European ones) as in 
case of India, which relates to building of national poli-
cies and regulations on traditional (complementary and 
alternative) medicines. This would support the proper 
use of traditional medicines; integrating them into the 
national health systems; building or strengthening the 
pharmacovigilance systems to monitor herbal medicines 
use; and promoting sound use of these medicines by con-
sumers and providers [16].
Conclusions
The traditional medicine plays a vital role in both the 
Indian and European health care systems and needs more 
research and development with due consideration to the 
philosophical concepts behind them. The research should 
focus more on public health dimensions along with clini-
cal research, reverse pharmacology and economic evalua-
tion. The standardization of drugs, enforcement of related 
laws and TRIPS should be strictly followed. It would be 
interesting to see what kind of light will be put on a par-
ticular traditional medicine by the currently popular sci-
entific approaches such as the Evidence Based Medicine 
or the Health Technology Assessment. This would provide 
more arguments in answering the question, if and which 
of the many traditional medicines or therapies should be 
covered by the national health insurance systems. 
Streszczenie:
Miejsce leków pochodzących z medycyny tradycyjnej
w indyjskim systemie opieki zdrowotnej
Słowa kluczowe: Ayurveda, Unani, Siddha, homeopatia, leki 
tradycyjne, Indie, Europa
Indie są jedynym krajem, który oficjalnie uznaje różnorodność syste-
mów medycznych, w tym takich jak: allopatia, Ayurveda, Yoga i natu-
ropatia, Unani, Siddha i homeopatia. Wielu Hindusów preferuje trady-
cyjne sposoby leczenia niektórych schorzeń, przy czym te preferencje 
nasilają się wraz ze stopniem zamożności i wykształcenia. Znaczna licz-
ba tradycyjnych metod leczniczych została opatentowana przez pod-
mioty zagraniczne, które następnie utrzymywały, że metody te stanowią 
„innowacje”, pomimo że były one już wcześniej publicznie dostępne. 
W ostatnich latach podjęte zostały w Indiach kroki zmierzające do ochro-
ny praw własności intelektualnej i kulturowej, przysługujących rdzennej 
ludności. Także w krajach europejskich stosowane są tradycyjne leki 
homeopatyczne, ziołowe, olejki eteryczne czy środki oparte na kwiatach. 
Badania kliniczne leków tradycyjnych różnią się od badań innych leków, 
stosownych badań farmakoekonomicznych zaś wciąż brakuje. Postępy 
w naukach medycznych powinny dostarczyć argumentów pomocnych 
w udzieleniu odpowiedzi na pytania, czy i które spośród leków tradycyj-
nych powinny być finansowane z publicznych środków finansowych.
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